Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Following ASCT for R/R B-NHL With High-Risk Prognostic Factors
NCT06365671Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Ruijin Hospital. Started Apr 2024; status: recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT06365671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365671.